Guanylate cyclase C Inhibitors
2 drugsAbout Guanylate cyclase C
Guanylate cyclase C (GC-C) is a transmembrane receptor that regulates fluid and electrolyte balance in the intestine.
GC-C is a drug target with two FDA-approved peptide drugs, LINZESS and TRULANCE, used to treat specific health conditions; however, there is no genetic evidence currently available to support this target.
LINZESS (AbbVie) and TRULANCE (SALIX) are the only approved drugs, both peptides, targeting GC-C, with applications in 'other' therapeutic areas.
Top Guanylate cyclase C Drugs
The competitive landscape includes AbbVie and SALIX with approved drugs.
Limited number of players suggests opportunity for new market entrants.
Guanylate cyclase C Drug Modality Landscape
Modalities
Routes of Administration
Guanylate cyclase C is primarily targeted by peptide modalities (100% of approved drugs).
Explore non-peptide modalities to differentiate from existing therapies.
Guanylate cyclase C Clinical Trials 44 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Guanylate cyclase C. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 | 100% |
| Phase 2 | 12 | 9 | 1 | 2 | 90% |
| Phase 3 | 21 | 21 | 0 | 0 | 100% |
| Phase 4 | 7 | 3 | 1 | 3 | 75% |
Top Sponsors
By Modality
Top Conditions
Guanylate cyclase C Drug Approval Timeline (2012 - 2017)
The first drug was approved in 2012 (LINZESS) and the most recent in 2017 (TRULANCE).
Slow approval rate indicates potential saturation or challenges in this target area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 17 (8 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Guanylate cyclase C. A trial counts if an approved drug acting on Guanylate cyclase C is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.